Fangjiomics: In Search of Effective and Safe Combination Therapies
Identifieur interne : 000793 ( Main/Exploration ); précédent : 000792; suivant : 000794Fangjiomics: In Search of Effective and Safe Combination Therapies
Auteurs : Wang [République populaire de Chine] ; Liu [République populaire de Chine] ; Cheng [République populaire de Chine] ; Wang [République populaire de Chine]Source :
- The Journal of Clinical Pharmacology [ 0091-2700 ] ; 2011-08.
English descriptors
- KwdEn :
Abstract
Millennia‐old Chinese medicine treats disease with many combination therapies involving ingredients used in clinic practice. Fangjiomics is the science of identifying and designing effective mixtures of bioactive agents and elucidating their modes of action beyond those of Chinese patent medicines. Omics profiling and quantitative optimal modeling have been used to associate the various responses with biological pathways related to disease phenotype. Fangjiomics seeks to study myriad compatible combinations that may act through multiple targets, modes of action, and biological pathways balancing on off‐target and on‐target effects. This approach may lead to the discovery of controllable array‐designed therapies to combine less potent elements that are more effective collectively but have fewer adverse side effects than does any element singly.
Url:
DOI: 10.1177/0091270010382913
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000757
- to stream Istex, to step Curation: 000757
- to stream Istex, to step Checkpoint: 000213
- to stream Main, to step Merge: 000795
- to stream Main, to step Curation: 000793
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Fangjiomics: In Search of Effective and Safe Combination Therapies</title><author><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name></author><author><name sortKey="Liu" sort="Liu" uniqKey="Liu" last="Liu">Liu</name></author><author><name sortKey="Cheng" sort="Cheng" uniqKey="Cheng" last="Cheng">Cheng</name></author><author><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0EA0943A6E0184924442A5D829ECE55B19373453</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1177/0091270010382913</idno><idno type="url">https://api.istex.fr/document/0EA0943A6E0184924442A5D829ECE55B19373453/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000757</idno><idno type="wicri:Area/Istex/Curation">000757</idno><idno type="wicri:Area/Istex/Checkpoint">000213</idno><idno type="wicri:doubleKey">0091-2700:2011:Wang:fangjiomics:in:search</idno><idno type="wicri:Area/Main/Merge">000795</idno><idno type="wicri:Area/Main/Curation">000793</idno><idno type="wicri:Area/Main/Exploration">000793</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Fangjiomics: In Search of Effective and Safe Combination Therapies</title><author><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Liu" sort="Liu" uniqKey="Liu" last="Liu">Liu</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author><author><name sortKey="Cheng" sort="Cheng" uniqKey="Cheng" last="Cheng">Cheng</name><affiliation wicri:level="4"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Pharmaceutical Research Institute, Zhejiang University</wicri:regionArea><placeName><settlement type="city">Hangzhou</settlement><region type="province">Zhejiang</region></placeName><orgName type="university">Université de Zhejiang</orgName></affiliation></author><author><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name><affiliation wicri:level="3"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing</wicri:regionArea><placeName><settlement type="city">Pékin</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">The Journal of Clinical Pharmacology</title><idno type="ISSN">0091-2700</idno><idno type="eISSN">1552-4604</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2011-08">2011-08</date><biblScope unit="volume">51</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1132">1132</biblScope><biblScope unit="page" to="1151">1151</biblScope></imprint><idno type="ISSN">0091-2700</idno></series><idno type="istex">0EA0943A6E0184924442A5D829ECE55B19373453</idno><idno type="DOI">10.1177/0091270010382913</idno><idno type="ArticleID">JCPH5434</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0091-2700</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Fangjiomics</term><term>array design</term><term>combination therapy</term><term>multicomponent therapeutic</term><term>pathways spectrum</term><term>target therapy</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Millennia‐old Chinese medicine treats disease with many combination therapies involving ingredients used in clinic practice. Fangjiomics is the science of identifying and designing effective mixtures of bioactive agents and elucidating their modes of action beyond those of Chinese patent medicines. Omics profiling and quantitative optimal modeling have been used to associate the various responses with biological pathways related to disease phenotype. Fangjiomics seeks to study myriad compatible combinations that may act through multiple targets, modes of action, and biological pathways balancing on off‐target and on‐target effects. This approach may lead to the discovery of controllable array‐designed therapies to combine less potent elements that are more effective collectively but have fewer adverse side effects than does any element singly.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li></country><region><li>Zhejiang</li></region><settlement><li>Hangzhou</li><li>Pékin</li></settlement><orgName><li>Université de Zhejiang</li></orgName></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name></noRegion><name sortKey="Cheng" sort="Cheng" uniqKey="Cheng" last="Cheng">Cheng</name><name sortKey="Liu" sort="Liu" uniqKey="Liu" last="Liu">Liu</name><name sortKey="Wang" sort="Wang" uniqKey="Wang" last="Wang">Wang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/CyberinfraV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000793 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000793 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Ticri/CIDE
|area= CyberinfraV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0EA0943A6E0184924442A5D829ECE55B19373453
|texte= Fangjiomics: In Search of Effective and Safe Combination Therapies
}}
| This area was generated with Dilib version V0.6.25. |  |